Is it or ain’t it “really” cancer?

In a new article in the Journal of Urology, researchers at Johns Hopkins Medical Center in Baltimore have again expressed their opinion that it would be inappropriate to rename low-risk Gleason 6 disease as something other than “cancer”. … READ MORE …

“Getting off biopsy train in prostate cancer”

“Getting off biopsy train in prostate cancer” is the title of the latest article by Howard Wolinsky (a long-time active active surveillance patient) on the MedPage Today web site. We recommend it to your attention. … READ MORE …

“Is prostate cancer screening right for you?”

The following infographic was also issued today by the U.S. Preventive Services Task Force (USPSTF) and offers guidance as to the appropriateness of prostate cancer screening for an average, 55- to 69-year-old American male with no specific, known risk factors for prostate cancer: … READ MORE …

How “average Americans” think about cancer today

Earlier this year the American Society for Clinical Oncology (ASCO) worked with the Harris Poll to put in place ASCO’s first annual National Cancer Opinion Survey. We thought many of our readers might be interested in the findings. … READ MORE …

Prostate cancer in men with advanced bladder cancer

A new article in the journal Urologic Oncology has highlighted an association between the occurrence of advanced bladder cancer and the related finding of prostate cancer among such patients who have their prostate removed along with their bladder at the time of initial surgery  for the bladder cancer (i.e., a radical cystoprostatectomy). … READ MORE …

Another step toward a rational, risk-stratified PSA testing methodology

A newly published article in the Journal of Clinical Oncology has suggested that PSA testing between 40 and 59 years of age may be able to predict for risk of clinically significant prostate cancer later in life. … READ MORE …

New form of vaccine therapy — for low-risk prostate cancer

According to a media report on the MarketWatch web site, a company called OncBioMune is to initiate Phase II clinical trials of a new type of prostate cancer vaccine (ProscaVax). … READ MORE …